Search

Issue
Title
Authors
The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
Bolotina L.V., Manziuk L.V., Gorbunova V.A., Kovalenko E.I., Mukhametshina G.Z., Khasanova A.I., Vladimirova L.Y., Mitashok I.S., Prokofyeva E.P., Evstigneeva I.V., Andreyashkina I.I., Abramova N.A., Popova I.L., Karabina E.V., Teterich A.A., Gaysina E.A., Chubenko V.A., Limareva S.V., Tikhanovskaya N.M., Storozhakova A.E., Samaneva N.Y., Svetitskaya Y.V., Snezhko T.A., Kalabanova E.A.
Radiation-induced lung injury in breast cancer patients after breast conservation therapy
Trofimova O.P., Tkachev S.I., Ivanov S.M., Utkina V.L., Cheban O.I., Glebovskaya V.V.
Tumor biology or adjuvant systemic therapy: what determines the risk of recurrence in breast cancer stage I?
Kolyadina I.V., Poddubnaya I.V., Trofimova O.P., Frank G.A., Karseladze A.I., Komov D.V.
Press-release. «Sanofi» makes a contribution in improving availability of treatment in women with breast cancer in Russia in accordance with international standards
The main markers of the long-term efficiency of neoadjuvant chemotherapy in breast cancer (review of literature)
Semiglazov V.F., Semiglazov V.V., Paltuev P.M., Nikolaev K.S., Dashyan G.A.
Current approach to adjuvant therapy for breast cancer (a review)
Conte P., Guarneri V.
Klinicheskaya effektivnost'i bezopasnost' primeneniya otechestvennogo rekombinantnogo granulotsitarnogo koloniestimuliruyushchego faktora Neypomaks® u bol'nykh rakom molochnoy zhelezy, poluchayushchikh khimioterapiyu doksorubitsinom i dotsetakselom
Zhukova L.G., Abramov M.E., Vakhabova Y.V., Lud A.N., Obukhov A.A., Lichinitser M.R.
Tayverb/Tyverb (lapatinib) – pervyy dvoynoy anti-ErbB1(EGFR)i anti-ErbB2(HER2)-ingibitor v lechenii mestno-rasprostranennogo i metastaticheskogo raka molochnoy zhelezy zaregistrirovan v Rossiyskoy Federatsii
Antiestrogennaya terapiya pri rake molochnoy zhelezy. Naskol'ko bezopasny ingibitory aromatazy?
Ptushkin V.V.
Aromazin: printsip deystviya
Imyanitov E.N.
Farmorubitsin v klinicheskoy praktike
Gorbunova V.A.
Analiz rezul'tatov vnedreniya Regional'noy rossiyskoy programmy lecheniya pervichno-generalizovannogo i metastaticheskogo raka molochnoy zhelezy v Voronezhskom oblastnom klinicheskom onkologicheskom dispansere
Chevardov N.I., Tolstykh L.V., Puzakov K.G., Potapov Y.N.
Breast cancer immunophenotype and its relationship with haematopoiesis
Ryabchikov D.A., Chulkova S.V., Shamilov F.A., Chanturia N.V., Zheltikov S.D., Tupitsyn N.N.
Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
Board E.
Opportunities of the pharmacogenetic approach to personalized tamoxifen breast cancer therapy: case reports
Savelyeva M.I., Dudina I.A., Zaharenkova J.S., Ignatova A.K., Ryzhikova K.A., Sozaeva Z.A., Kudlay D.A., Perfileva O.M., Poddubnaya I.V.
Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
Kolbin A.S., Mosikyan A.A., Balykina Y.E., Proskurin M.A.
Bioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients: findings of the international, double-blind phase III clinical study
Ignatova E.O., Burdaeva O.N., Kopp M.V., Kotiv B.N., Udovitsa D.P., Stroiakovskii D.L., Alekseev S.M., Sheveleva L.P., Khorinko A.V., Shapovalova I.S., Moiseenko V.M., Ivanov R.A.
Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy
Krivorotko P.V., Burdaeva O.N., Nechaeva M.N., Frolova M.A., Kopp M.V., Abrosimova A.A., Ivanov R.A.
Rezul'taty «Epidemiologicheskoy programmy skrininga HER2-statusa u bol'nykh rakom molochnoy zhelezy» v Rossiyskoy Federatsii
Frank G.A., Poddubnaya I.V., Yagudina R.I., Borisov D.A.
Klinicheskiy sluchay effektivnogo lecheniya lapatinibom (Tayverb)i kapetsitabinom (Kseloda) bol'noy disseminirovannym rakom molochnoy zhelezy s giperekspressiey ErbB2 (Her-2/neu) s metastaticheskim porazheniem veshchestva i obolochek golovnogo mozga
Naskhletashvili D.R., Chmutin G.E.
Bevatsizumab (Avastin) v kombinatsii s taksanami v 1-y linii lecheniya HER-2-negativnogo metastaticheskogo raka molochnoy zhelezy(Rezul'taty issledovaniya AVADO)
Zhukova L.G.
Femara (letrozol) v sovremennoy terapii raka molochnoy zhelezy
Perevodchikova N.I.
8 let nadezhdy: novye dannye issledovaniya ATAS
Primenenie Zomety na fone endokrinnoy terapii Femaroy u bol'nykh rakom molochnoy zhelezy s metastazami v kosti
Konstantinova M.M., Ovchinnikova L.K., Lomakin N.N., Galleev M.G., Neretina E.S., Mukhamedshina G.Z., Mukhametgaleeva F.K.
Immunogistokhimicheskoe opredelenie ekspressii HER2/neu pri rake molochnoy zhelezy (po dannym Smolenskogo oblastnogo onkologicheskogo klinicheskogo dispansera)
Shisterova O.A., Golik E.P.
Aromazin (ekzemestan) v neoad\"yuvantnoy i ad\"yuvantnoy gormonoterapii raka molochnoy zhelezy
Makarenko N.P.
Znachenie taksanov v neoad\"yuvantnoy terapii raka molochnoy zhelezy
Bozhok A.A., Semiglazov V.F., Kletsel' A.E., Arzumanov A.S., Ivanova O.A., Semiglazov V.V.
Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
Board E.
Circulating tumor cell: biology, methods of isolation, clinical significance in breast cancer
Nenahova Y.N., Lyadov V.K., Poddubnaya I.V.
The results of epidemiological screening program of HER2 status in patients with breast cancer in the federal districts of the Russian Federation in 2015
Poddubnaya I.V., Frank G.A., Yagudina R.I., Koroleva N.I., Zavalishina L.E.
Stereotactic biopsy of breast lesions under x-ray control
Manikhas G.M., Safronova O.B., Khudjakova T.G., Barabanova L.P., Punanova N.J.
Personalized approach to HER2-positive advanced breast cancertherapy
Stenina M.B.
Bone mineral density in patient with breast cancer
Poddubnaya I.V., Kizhaev E.V., Kolyadina I.V., Banov S.M., Zhmaeva E.M., Secko M.A.
Predoperatsionnaya (neoad\"yuvantnaya) endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy
Semiglazov V.F., Semiglazov V.V., Zhil'tsova E.K.
Kachestvo zhizni i simptomyu bol'nykh disseminirovannym gormonopozitivnym rakom molochnoy zhelezy v postmenopauze na fone primeneniya Fazlodeksa
Novik A.A., Ionova T.I., Kalyadina S.A.
Femara (letrozol) v ad\"yuvantnoy terapii raka molochnoy zhelezy
Stenina M.B.
Vliyanie rekonstruktivno-plasticheskikh operatsiy na kachestvo zhizni bol'nykh rakom molochnoy zhelezy v otdalennom periode
Arslanov K.S., Tkachenko G.A.
Opyt primeneniya Taksotera v kombinatsii s doksorubitsinom v kachestve khimioterapii 1-y linii u bol'nykh metastaticheskim rakom molochnoy zhelezy
Samoylenko V.M., Gorbunova V.A., Koshelev M.N., Yurashko K.V.
Faktory prognoza pri rake molochnoy zhelezy
Bozhok A.A., Semiglazov V.F., Semiglazov V.V., Arzumanov A.S., Kletsel' A.E.
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
Board E.
Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
Board E.
Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor
Ganshina I.P., Ivanova K.A., Lubennikova E.V., Arkhipov A.V., Zhukova L.G.
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
Kolyadina I.V., Ganshina I.P., Kuzmicheva S.V., Tekeeva A.I., Kolokolov J.D., Volkonskii M.V., Poddubnaya I.V.
Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population
Grechukhina K.S., Zhukova L.G.
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
Gorbunova V.A., Kolyadina I.V., Kovalenko E.I., Manziuk L.V., Artamonova E.V., Zhukova L.G., Bolotina L.V., Semiglazova T.I., Manikhas A.G., Raevskaia N.A., Itkin I.M., Filonenko D.V., Zhilyaeva L.A., Gol'dberg V.E., Popova N.O., Ponomarenko D.M., Shikina V.E., Suslova I.R., Romanchuk O.V., Kozlov D.V., Rzaev A.S., Marfutov V.V., Andreiashkina I.I., Vladimirova L.I., Mitashok I.S., Tikhanovskaia N.M., Karabina E.V., Mukhametshina G.Z., Khasanova A.I., Safina S.Z., Shaidorov M.V., Morozov D.A., Prokof'eva E.P., Kramskaia L.V., Karandeeva T.V., Evstigneeva I.V., Ovchinnikova E.G., Klement'eva T.P., Khrupalo O.V., Tiuvinova E.V., Sherstnev V.M., Chernov I.S., Kolokolov D.D., Gaisina E.A., Levchenko N.V., Chubenko V.A., Povyshev A.I., Iudina I.V., Vorotilina L.V., Andreeva T.V., Tumanian G.S., Koziakov A.E., Gil'mutdinova L.A., Osipov M.A., Shatokhina A.S., Vazhenina A.A., Chichkanova A.S., Vladimirov V.I., Ivanov A.N., Belokhvostova A.S., Cherniakova E.M., Tul'china E.A., Maklashova S.A., Shkodenko O.N., Kostalanova I.V., Tarasova A.V., Kuz'mina E.S.
Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0
Pavlikova O.A., Poddubnaya I.V., Kolyadina I.V., Abdullaev A.G., Komov D.V., Danzanova T.Y., Sinyukova G.T., Kozlov N.A., Ganshina I.P., Zhukova L.G., Aliyeva G.S., Kerimov R.A., Gordeeva O.O.
Pharmacoeconomic characteristics of ixabepilone (Ixempra) monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
Kolbin A.S., Mosikyan A.A., Kurilev A.A., Balykina Y.E., Proskurin M.A.
Fulvestrant in endocrine therapy of recurrent and metastatic breast cancer
Vladimirova L.Y.
Brain metastases in her2-positive breast cancer: new opportunities for systemic therapy
Artamonova E.V., Manziuk L.V.
High efficiency of lapatinib in combination with capecitabine in patient with metastatic HER2-positive synchronous breast cancer (case study)
Seryakov A.P., Ovchinnikova L.K., Zabelin M.V., Yakubov T.Z., Sidorov D.B., Ovchinnikov M.V.
New possibilities of chemotherapy for anthracyclineand/or taxane-resistant breast cancer
Artamonova E.V., Manzyuk L.V.
Aromazin v ad\"yuvantnoy terapii raka molochnoy zhelezy
Artamonova E.V.
HER-2-targetnaya terapiya raka molochnoy zhelezy: monoklonal'nye antitela i ingibitory tirozinkinazy
Ognerubova I.N.
Regional'naya programma lecheniya bol'nykh pervichno-generalizovannym i metastaticheskim rakom molochnoy zhelezy
Ad\"yuvantnaya endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy
Semiglazov V.F., Semiglazov V.V.
Biologicheskie kharakteristiki opukholi (proliferativnaya aktivnost', ploidnost' i steroidnye retseptory) i ikh vliyanie na neposredstvennye i otdalennye rezul'taty lecheniya zapushchennogo raka molochnoy zhelezy
Nikolaeva T.G., Vyshinskaya G.V., Rotobel'skaya L.E.
101 - 156 of 156 Items << < 1 2 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies